A novel animal model to study non-spontaneous bisphosphonates osteonecrosis of jaw

Journal of Oral Pathology and Medicine

Volumn 39, Issue 5, 2010, Pages 390-396

  Biasotto, Matteo ^a   Chiandussi, Silvia ^a   Zacchigna, Serena ^b   Moimas, Silvia ^b   Dore, Franca ^c   Pozzato, Gabriele ^c   Cavalli, Fabio ^c   Zanconati, Fabrizio ^a   Contardo, Luca ^a   Giacca, Mauro ^b   Di Lenarda, Roberto ^a  

^a UNIVERSITY OF TRIESTE   (Italy)

^b INTERNATIONAL CENTRE FOR GENETIC ENGINEERING AND BIOTECHNOLOGY   (Italy)

^c MAGGIORE HOSPITAL   (Italy)

Author keywords

Animal model; Bisphosphonates; Bone; Jaws; Osteonecrosis

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CONTRAST MEDIUM; ZOLEDRONIC ACID; BONE DENSITY CONSERVATION AGENT; IMIDAZOLE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE DEFECT; BONE DESTRUCTION; BONE SCINTISCANNING; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; EPITHELIZATION; FEMALE; FRACTURE HEALING; IMAGING; JAW OSTEONECROSIS; MICROSCOPY; NONHUMAN; OSTEOCYTE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RAT; ANIMAL; BONE NECROSIS; CHEMICALLY INDUCED; DISEASE MODEL; INTRAVENOUS DRUG ADMINISTRATION; JAW DISEASE; REPRODUCIBILITY; SCINTISCANNING; TOOTH EXTRACTION; WISTAR RAT;

ANIMALS; BONE DENSITY CONSERVATION AGENTS; DIPHOSPHONATES; DISEASE MODELS, ANIMAL; FEMALE; IMIDAZOLES; INJECTIONS, INTRAVENOUS; JAW DISEASES; MAXILLARY DISEASES; OSTEONECROSIS; RATS; RATS, WISTAR; REPRODUCIBILITY OF RESULTS; TOOTH EXTRACTION;

EID: 77951272653     PISSN: 09042512     EISSN: 16000714     Source Type: Journal    
DOI: 10.1111/j.1600-0714.2009.00878.x     Document Type: Article

References (49)

1. Nussbaum SR, Younger J, Vandepol CJ, et al. Single-dose intravenous therapy with pamidronate for the treatment of hypercalcemia of malignancy: comparison of 30-, 60-, and 90-mg dosages. Am J Med 1993 95 : 297 304.
2. Major P, Lortholary A, Hon J, et al. Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: a pooled analysis of two randomized, controlled, clinical trials. J Clin Oncol 2001 19 : 558 567.
3. Hillner BE, Ingle JN, Chlebowski RT, et al. American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. J Clin Oncol 2003 21 : 4042 4057.
4. Rosen LS, Gordon D, Tchekmedyian NS, et al. Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with non-small cell lung carcinoma and other solid tumors: a randomized, Phase III, double-blind placebo-controlled trial. Cancer 2004 100 : 2613 2621.
5. Lipton A. Efficacy and safety of intravenous bisphosphonates in patients with bone metastases caused by metastatic breast cancer. Clin Breast Cancer 2007 7 : S14 20.
6. Dhillon S, Lyseng-Williamson KA. Zoledronic acid: a review of its use in the management of bone metastases of malignancy. Drugs 2008 68 : 507 534.
7. Marx RE. Pamidronate (Aredia) and Zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg 2003 61 : 115 117.
8. Biasotto M, Chiandussi S, Dore F, et al. Clinical aspects and management of bisphosphonates-associated osteonecrosis of the jaws. Acta Odontol Scand 2006 64 : 348 354. (Pubitemid 44845517)
9. Hess LM, Jeter JM, Benham-Hutchins M, Alberts DS. Factors associated with osteonecrosis of the jaw among bisphosphonate users. Am J Med 2008 121 : 475 483.
10. Sambrook PN, Ebeling P. Osteonecrosis of the jaw. Curr Rheumatol Rep 2008 10 : 97 101.
11. Pendrys DG, Silverman SL. Osteonecrosis of the jaws and bisphosphonates. Curr Osteoporos Rep 2008 6 : 31 8.
12. Parisuthiman D. Bisphosphonate-related osteonecrosis of the jaws: a call for multidisciplinary approaches. J Med Assoc Thai 2007 90 : 2699 2708.
13. Valverde P. Pharmacotherapies to manage bone loss-associated diseases: a quest for the perfect benefit-to-risk ratio. Curr Med Chem 2008 15 : 284 304.
14. Ruggiero SL, Woo SB. Bisphosphonate-related osteonecrosis of the jaws. Dent Clin North Am 2008 52 : 111 128.
15. Sawatari Y, Marx RE. Bisphosphonates and bisphosphonate induced osteonecrosis. Oral Maxillofac Surg Clin North Am 2007 19 : 487 498.
16. Adamo V, Caristi N, Saccà MM. Current knowledge and future directions on bisphosphonate-related osteonecrosis of the jaw in cancer patients. Expert Opin Pharmacother 2008 9 : 1351 1361.
17. Aapro M, Abrahamsson PA, Body JJ. Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panel. Ann Oncol 2008 19 : 420 432.
18. Mehrotra B. Safety profile of intravenous bisphosphonates. Semin Oncol 2007 34 : S24 7.
19. Van Den Wyngaert T, Huizing MT, Vermorken JB. Osteonecrosis of the jaw related to the use of bisphosphonates. Curr Opin Oncol 2007 19 : 315 322.
20. Sarin J, Derossi SS, Akintoye SO. Updates on bisphosphonates and potential pathobiology of bisphosphonate-induced jaw osteonecrosis. Oral Dis 2008 14 : 277 285.
21. Bertoldo F, Santini D, Lo Cascio V. Bisphosphonates and osteomyelitis of the jaw: a pathogenic puzzle. Nat Clin Pract Oncol 2007 4 : 711 721.
22. Reid IR, Bolland MJ, Grey AB. Is bisphosphonate-associated osteonecrosis of the jaw caused by soft tissue toxicity? Bone 2007 41 : 318 320.
23. Migliorati CA, Shubert MM, Peterson DE, Seneda LM. Bisphosphonates- associated osteonecrosis of mandibular and maxillary bone: an emerging oral complication of supportive cancer therapy. Cancer 2005 104 : 83 93.
24. Ruggiero SL, Mehrotra B, Rosenberg TJ, Engroff SL. Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J Oral Maxillofac Surg 2004 62 : 527 534.
25. Fleisch H. Bisphosphonates: mechanisms of action. Endocr Rev 1998 19 : 80 100.
26. Hughes DE, Macdonald BR, Russell RG, Gowen M. Inhibition of osteoclast-like cell formation by bisphosphonates in long-term cultures of human bone marrow. J Clin Invest 1989 83 : 1930 1935.
27. Santini D, Vincenzi B, Avvisati G, et al. Pamidronate induces modifications of circulating angiogenetic factors in cancer patients. Clin Cancer Res 2002 8 : 1080 1084.
28. Saad F, Gleason DM, Murray R, et al. Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst 2004 96 : 879 882. (Pubitemid 38807610)
29. Hegarty A, Georgakopolou E, Porter S. Bisphosphonate-related osteochemonecrosis of the jaws. Br J Hosp Med 2008 69 : 158 162.
30. Bamias A, Kastritis E, Bamia C, et al. Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors. J Clin Oncol 2005 23 : 8580 8587.
31. Dimopoulos M, Kastritis E, Moulopoulos LA, et al. The incidence of osteonecrosis of the jaw in patients with multiple myeloma who received bisphosphonates depends on the type of bisphosphonate. Blood (American Society of Hematology Annual Meeting Abstracts) 2005 106 : 637.
32. Tosi P, Zamagni E, Cangini D, et al. Bisphosphonates and osteonecrosis of the jaws: incidence in a homogeneous series of patients with newly diagnosed multiple myeloma treated with zoledronic acid. Blood (American Society of Hematology Annual Meeting Abstracts) 2005 106 : 3461.
33. Pozzi S, Marcheselli R, Sacchi S, et al. Analysis of frequency and risk factors for developing bisphosphonate associated necrosis of the jaw. Blood (American Society of Hematology Annual Meeting Abstracts) 2005 106 : 5057.
34. Carter G, Goss AN, Doecke C. Bisphosphonates and avascular necrosis of the jaw: a possible association. Med J Aust 2005 182 : 413 415.
35. Fournier P, Boissier S, Filleur S, et al. Bisphosphonates inhibit angiogenesis in vitro and testosterone-stimulated vascular regrowth in the ventral prostate in castrated rats. Cancer Res 2002 62 : 6538 6544.
36. Bauss F, Pfister T, Papapoulos S. Ibandronate uptake in the jaw is similar to long bones and vertebrae in the rat. J Bone Miner Metab 2008 26 : 406 408.
37. Brouwers JE, Lambers FM, Gasser JA, Van Rietbergen B, Huiskes R. Bone degeneration and recovery after early and late bisphosphonate treatment of ovariectomized wistar rats assessed by in vivo micro-computed tomography. Calcif Tissue Int 2008 82 : 202 211.
38. Mcdonald MM, Dulai S, Godfrey C, Amanat N, Sztynda T, Little DG. Bolus or weekly zoledronic acid administration does not delay endochondral fracture repair but weekly dosing enhances delays in hard callus remodelling. Bone 2008 43 : 653 662.
39. Lühe A, Künkele KP, Haiker M, et al. Preclinical evidence for nitrogen-containing bisphosphonate inhibition of farnesyl diphosphate (FPP) synthase in the kidney: implications for renal safety. Toxicol In Vitro 2008 22 : 899 909.
40. Gasser JA, Ingold P, Venturiere A, Shen V, Green JR. Long-term protective effects of zoledronic acid on cancellous and cortical bone in the ovariectomized rat. J Bone Min Res 2008 23 : 544 551.
41. Lamoureux F, Ory B, Battaglia S, et al. Relevance of a new rat model of osteoblastic metastases from prostate carcinoma for preclinical studies using zoledronic acid. Int J Cancer 2008 15 : 751 760.
42. Yao W, Cheng Z, Koester KJ, et al. The degree of bone mineralization is maintained with single intravenous bisphosphonates in aged estrogen-deficient rats is a strong predictor of bone strength. Bone 2007 41 : 804 812.
43. Aspenberg P, Wermelin K, Tengwall P, Fahlgren A. Additive effects of PTH and bisphosphonates on the bone healing response to metaphyseal implants in rats. Acta Orthop 2008 79 : 111 115.
44. Heino TJ, Chagin AS, Takigawa M, Sävendahl L. Effects of alendronate and pamidronate on cultured rat metatarsal bones: failure to prevent dexamethasone-induced growth retardation. Bone 2008 42 : 702 709.
45. Badros A, Weikel D, Salama A, et al. Osteonecrosis of the jaw in multiple myeloma patients: clinical features and risk factors. J Clin Oncol 2006 24 : 945 952.
46. Chiandussi S, Biasotto M, Dore F, Cavalli F, Cova MA, Di Lenarda R. Clinical and diagnostic imaging of bisphosphonate-associated osteonecrosis of the jaws. Dentomaxiollofac Radiol 2006 35 : 236 243. (Pubitemid 44076879)
47. Dore F, Filippi L, Biasotto M, Chiandussi S, Cavalli F, Di Lenarda R. Bone-scintigraphy and SPECT/CT imaging of biphosphonate-induced osteo- necrosis of the jaws. J Nuclear Med 2009 50 : 30 5.
48. Allen MR. Animal models of osteonecrosis of the jaw. J Musculoskelet Neuronal Interact 2007 7 : 358 360.
49. Sonis ST, Watkins BA, Lyng GD, Lerman MA, Anderson KC. Bony changes in the jaws of rats treated with zoledronic acid and dexamethasone before dental extraxtions mimic bisphosphonates-related osteonecrosis in cancer patients. Oral Oncol 2009 45 : 164 172.